Burnaby, British Columbia – October 17, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
Burnaby, British Columbia – September 26, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead
Burnaby, British Columbia – July 20, 2022 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific […]
Read More >
Qu Biologics Closes USD$12M Equity Financing
Burnaby, British Columbia – March 21, 2022 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific […]
Read More >
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
Vancouver, British Columbia – July 13, 2021 – Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators […]
Read More >